Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. - Investigators sought to assess the effectiveness and safety of etrasimod in people with moderately to severely active ulcerative colitis (UC). In phase 2, proof-of-concept, double-blind, parallel-group study, they randomly selected adult outpatients with modified Mayo Clinic scores (MCSs) of 4–9, endoscopic subscores of 2 or more, and rectal bleeding subscores of 1 or more to groups given once-daily etrasimod 1 mg (n = 52) etrasimod 2 mg (n = 50), or placebo (n = 54) for 12 weeks. The study was performed at 87 centers in 17 countries from October 15, 2015, through February 14, 2018. It was found that the individuals with moderately to severely active ulcerative colitis, in comparison with placebo, etrasimod 2 mg was more effective in producing clinical and endoscopic improvements.